Wistar Recruits Jozef Madzo, Ph.D., as Director of Bioinformatics
Wistar InstituteJozef Madzo, Ph.D., recruited as an assistant professor and director of Bioinformatics, at The Wistar Institute.
Jozef Madzo, Ph.D., recruited as an assistant professor and director of Bioinformatics, at The Wistar Institute.
The Wistar Institute's Dr. Noam Auslander was awarded a $600,000 Women Scientists Innovation Award for Cancer Research grant from the V Foundation for Cancer Research to support the next three years of her research, which will use proteins of gut bacteria to predict immunotherapy benefit in melanoma.
Wistar scientists have built upon BTE technology to develop new and improved recombinant and synthetic DNA versions of therapeutic antibodies that target CA9, called Persistent Multivalent T Cell Engager (CA9-PMTE), that shows promise in pre-clinical models as a potent, long-lasting treatment against ccRCC.
Wistar Institute’s Paul M. Lieberman, Ph.D., and lab, have demonstrated how B cells infected with the Epstein-Barr virus (EBV) can contribute to a pathogenic, inflammatory phenotype that contributes to multiple sclerosis (MS); the group has also shown how these problematic B cells can be selectively targeted in a way that reduces the damaging autoimmune response of multiple sclerosis.
Wistar was awarded a $649,971 grant from the National Science Foundation (NSF) to support the continued expansion of its award-winning Biomedical Technician Training (BTT) Pre-apprenticeship Program.
The Wistar Institute assistant professor Dr. Filippo Veglia has discovered a key mechanism of how glioblastoma — a serious and often fatal brain cancer — suppresses the immune system so that the tumor can grow unimpeded by the body’s defenses.
Results of a new clinical trial published in Nature Medicine show that a novel, personalized neoantigen vaccine therapy demonstrated promising anti-tumor efficacy in patients with liver cancer who failed their original front-line treatment. The foundational biomedical research leading to this important study and important outcome originated from research in the Vaccine & Immunotherapy Center at The Wistar Institute.
Wistar's Dr. Abdel-Mohsen has identified sugar abnormalities in the blood that may promote biological aging and inflammation in people living with HIV.
The Wistar Institute Appoints Max Berger to its Board of Trustees
Wistar Institute’s Dr. Mohamed Abdel-Mohsen has demonstrated a connection between viral damage to the gut and premature biological aging.
Wistar Institute is pleased to announce the recruitment of Irene Bertolini, Ph.D., to pursue research in breast and brain cancers.
Jessie Villanueva, Ph.D., is one of the recipients of the 2024 Diversity in Business Award from the Philadelphia Business Journal.
The Wistar Institute is pleased to announce the recruitment of Filippo Veglia, Ph.D., to the Ellen and Ronald Caplan Cancer Center, where he joins Wistar’s Immunology, Microenvironment and Metastasis Program as an Assistant Professor.
The Wistar Institute is pleased to welcome Aleister Saunders, Ph.D., and Patrick Oates, Ph.D., to its Board of Trustees. The two new trustees bring a wealth of experience in biomedical research, technology transfer, and drug development to Wistar’s mission.
Wistar researchers successfully tested a simple intervention that could unlock greater anti-tumor power in therapies that use T cells — an approach known as “cell-based therapy,” which uses specially designed T cells to fight cancer.
Dario C. Altieri, M.D. — The Wistar Institute’s president and CEO, director of its Ellen and Ronald Caplan Cancer Center and the Robert & Penny Fox Distinguished Professor — is a recipient of the 2023 Most Admired CEO Awards recognized by the Philadelphia Business Journal for his leadership and service to Wistar.
The Wistar Institute announces the appointment of Dean Stoios as Chief Financial Officer.
Dario C. Altieri, M.D., Wistar president and CEO, will be honored by the Justinian Foundation and Society of Philadelphia for exemplifying the finest qualities of scholarship, civic leadership and integrity.
Zachary Schug, Ph.D., assistant professor at The Wistar Institute, has published a new paper in the journal Nature Cancer demonstrating a double-acting mechanism for fighting a particularly aggressive, difficult-to-treat form of breast cancer.
Wistar is pleased to announce the recruitment of Avi Srivastava, Ph.D., to the Ellen and Ronald Caplan Cancer Center, where he joins Wistar’s Gene Expression and Regulation Program as an Assistant Professor.